logo
logo

Tris Pharma Announces Acquisition Of New, Late-Stage Drug Candidate For Pain

Tris Pharma Announces Acquisition Of New, Late-Stage Drug Candidate For Pain

12/07/22, 12:37 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgmonmouth junction
Industry
pharmaceutical manufacturing
Tris Pharma, Inc. ("Tris"), a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, today announced that it has acquired rights to TRN-261 a non-opioid drug candidate that Tris intends to develop for multiple indications within acute and chronic pain.

Company Info

Company
Tris Pharma
Location
Monmouth Junction, New Jersey, United States
Company info
Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients’ needs in neuroscience and other therapeutic categories.

Related People